Barbieri Antonio1, Palma Giuseppe1, Rosati Alessandra2 , Petrillo Antonella1,Di Benedetto
Maria3, Longobardi Amelia3, Aldo Giudice1, Caterina Turco2, Arra Claudio1
1 Istituto Nazionale Tumori Fondazione “G.Pascale” Napoli.
2 Dipartimento di Scienze Farmaceutiche - Università degli Studi di Salerno - Fisciano
3 Dipartimento di Clinica Medica e Sperimentazione Sezione Istologica del Policlinico Università Federico II Napoli
Clinical studies indicate that stress, chronic depression, social support and other psychological
factors may influence cancer progression. Recent studies have identified biological signalling
pathways that could contribute to such effects even if the influence of the stress on some
tumors is not yet well understood. Environmental and psycho-social processes initiate a cascade
of information-processing pathways in the central nervous system (CNS) and periphery, which
subsequently trigger fight-or-flight stress responses in the autonomic nervous system (ANS), or
defeat/ withdrawal responses produced by the hypothalamic–pituitary–adrenal axis (HPA). In
the figure 1 , are reported the areas of the brain thought to be responsible for mediating
stress responses and their effects on the adrenal glands and other target tissues. HPA
responses are mediated by hypothalamic production of corticotrophin releasing factor and
arginine vasopressin, both of which activate the secretion of pituitary hormones such as
adrenocorticotropic hormone (ACTH), enkephalins and endorphins. ACTH induces downstream
release of glucocorticoids such as cortisol from the adrenal cortex. Glucocorticoids control
growth, metabolism and immune function. We show that in mice which undergo to stress
condition of restraint one week before tumor injection of B16-F10 murine melanoma cell line, the
tumor burden increases of 200% respect to control group, and 120% in mice treated with
Figure 1 : Effects of stress-associated
factros on the tumor microenvironment.
Measure of ACTH and glucose
Figure 2: Measure of glucose and ACTH
levels in different groups of treatment.
Figure 3: FACs analisys of timocyte with
annexin V and iodure propidie. On the rihgt
the control mice and on the left the
tumor growth C57BL/6
Figure 4: B16 cells IHC with anti-VEGF at
20x, a) Control, b) Placebo+daily stress, c)
days post tumor injection
Figure 6: Tumor Growth of B16F10 cell line
Figure 5: A) Western Blot analysis of
Figure 7: Magnetic resonance imaging (MRI). Melanoma B16 coronal
expression of VEGF in B16F10 cell line.
planes image T1-weighted (400/13) enhanced Gd-DTPA. a) Image
B) Western Blot analysis of eNOS level
with central tumor necrosis of the posterior right leg; b) Image of
expression in B16F10 cell line.
the tumor treated with stress + propranolol; c) Image of tumor
treated with stress that present a significative central necrosis
respect to other groups.
These data suggest that the stress influences the tumor progression and growth by activaction of β adrenergic
receptor and increases glucorticoids levels that induce a upregulation of VEGF and increase of eNOS levels. High
levels of eNOS induce expression of iNOS that produces an increase in VEGF expression and thymic atrophy by
induction of apoptosis of T cells. These finding suggest that the stress influences also tumors not “strictly”
hormone–dependent as melanoma. These mechanisms activated by the stress, help to understand new pathway
involved in tumor progression and could represent new strategies for protecting individuals with cancer from the
detrimental effects of stress biology on the progression of malignant disease. Our next goal is to discover new
drugs by double action in order to block tumor progression induced by stress, without somministration of more
drugs to the patient that could be dangerous in the time.
The State of the Individual MarketThe Problems Facing the Individual Health Insurance Market in Massachusetts Insurers limit care by offering those in the individual market weak benefits, and sometimes excluding benefits all together. Insurers will sometimes even cancel an insurance policy once a customer starts making costly claims. Study after study has documented that people with pre-existing
Seasonal Influenza Report 2010-11 San Mateo County Health System, Public Health Week 4 (January 23-29, 2011) · r Reporting: 650.573.2346 · 650.573.2919 (fax) Volume 3, Issue 7 (Issued February 8, 2011) Karen Relucio MD, Assistant Health Officer · Suvas Patel, MPH, Epidemiologist · Scott Morrow MD, MPH, Health Officer Current Activity Percentage of Positive